Potential M1 muscarinic agonists have been synthesized in our laboratory based on Schulman's model of the muscarinic pharmacophore. Schulman's model [1] is based on detailed conformational analyses of known muscarinic agonists. Muscarinic agonists are currently therapeutic targets for the symptomatic treatment of Alzheimer's disease. The cholinergic hypothesis advanced by Schulman is based on the fact that, while neurons ...